Drawing for LONGEVIA GENOMICS

USPTO serial 99554129

LONGEVIA GENOMICS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
LEE, SANG MIN
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).

Status 686: Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance.

Need help with LONGEVIA GENOMICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mark A. Jansen

Mark A. Jansen Fenwick & West LLP801 California StreetMountain View, CA 94041United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment and prevention of diseases, disorders and conditions in the fields of oncology and immunology; veterinary preparations for treatment and prevention of diseases, disorders and conditions in the fields of oncology and immunology; sanitary preparations for medical purposes; diagnostic preparations for medical purposes; reagents for use in diagnostic tests for medical use; chemical diagnostic reagents for medical use; chemical preparations for testing blood for medical purposes; chemical preparations for use in DNA analysis for medical purposes; chemical reagents for medical or veterinary purposes; chemical test reagents, namely, for use in testing and evaluating DNA, genetics, and biological specimens clinical diagnostic reagents, namely, for use in testing and evaluating DNA, genetics, and biological specimens; clinical medical reagents; contrast media for use in medical imaging; diagnostic agents for medical use; diagnostic testing materials, namely, reagents and assays for testing DNA, genetics and biological specimens for medical use; genetic identity tests comprised of reagents for medical purposes; medical diagnostic test strips for testing DNA, genetics and biological specimens; indicators, namely, strips, pellets, films and liquids for medical diagnosis, namely, chemical, biological and genetic indicators for medical diagnosisACTIVE—
010Apparatus for use in medical analysis of DNA, genetics and biological specimens; apparatus for carrying-out diagnostic tests for medical purposes for testing DNA, genetics and biological specimens; diagnostic apparatus for medical purposes for testing and analyzing DNA, genetics and biological specimens; medical diagnostic instruments for detecting diseases, disorders and conditions in oncology and immunology; blood testing apparatus; medical and veterinary apparatus and instruments, namely, testing apparatus for testing DNA, genetics and biological specimens; medical apparatus for taking body fluid samples; medical apparatus for tumor diagnosis; automated medical analyzers for body fluids; medical diagnostic, examination, and monitoring equipment, namely, apparatus for DNA testing for identifying, preventing and managing diseases, disorders and conditions for medical purposes in the fields of oncology and immunology; filters for blood and blood components for medical purposes; fluid collection containers for medical use; medical instruments for extracting human body fluids; electronic analyzers for medical purposes for analyzing DNA, genetics and biological specimens; automated medical analyzers for foreign matter contained in body fluids; automatic analyzers for medical diagnosis of diseases, disorders and conditions in the fields of oncology and immunology; electromedical diagnostic instruments for testing DNA, genetics and biological specimens; genetic testing apparatus for medical purposesACTIVE—
042Scientific and technological services, namely, management and analysis, namely, genomics management and analysis of biorepository data; scientific services, namely, medical and scientific research in the field of genetics, pharmaceuticals, oncology, and immunology and research and design relating thereto; industrial analysis and research services in the fields of medicine, genetics and pharmaceuticals; development of computer hardware and software; research relating to molecular sciences; scientific analysis in the field of molecular biology; medical research; medical laboratory services; medical and pharmacological research services; scientific research for medical purposes on biorepository data in the field of genetics, pharmaceuticals, oncology and immunology; design and development of medical technology; computer programming in the medical field analysis of human tissues for medical research; biological research, clinical research on biorepository data in the field of genetics, pharmaceuticals, oncology and immunology; design and development of medical diagnostic apparatus; scientific research for medical purposes in the area of cancerous diseases; provision of information and data relating to medical and veterinary research and development; microbiological testing in the field of diseases, disorders and conditions in the fields of oncology and immunology; biotechnology testing in the field of diseases, disorders and conditions in the fields of oncology and immunology; laboratory testing in the field of diseases, disorders and conditions in the fields of oncology and immunology; scientific research and testing services in the fields of bacteriology and virology; genetic scientific research; genetic engineering services; DNA screening for scientific research purposes; medical laboratory services, namely, laboratory analysis services relating to the treatment of persons, namely, testing and analysis of biorepository data, DNA, genetics and biological specimensACTIVE—
044Medical services; genetic counseling; health screening services for diseases, disorders and conditions in the fields of oncology and immunology; providing health information; performing diagnosis of diseases; RNA or DNA services analysis for cancer diagnosis and prognosis; medical analysis services for cancer diagnosis and prognosis; genetic testing for medical purposes; medical and health care services relating to DNA, genetics and genetic testing; DNA screening for medical purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 3, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 3, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 28, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 9, 2026ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Oct 2, 2026ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Sep 25, 2026ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Sep 18, 2026ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Sep 8, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 27, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 27, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 27, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 22, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 22, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 22, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 1, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 1, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 1, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 23, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 23, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 23, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 21, 2026DOCKASSIGNED TO EXAMINER—
Apr 9, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 17, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 17, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance